- Open Access
Exercise intensity in cancer survivors: a matter of the heart
© The Author(s). 2017
- Received: 2 March 2017
- Accepted: 2 March 2017
- Published: 13 March 2017
A routine of regular aerobic exercise has been shown to have non-pharmacological benefits for the prevention and treatment of many potential side effects from chemotherapy. This includes the whole spectrum of cancer care from diagnosis through treatment and long-term survivorship. The case report by Korn et al that accompanies this editorial describes an adolescent leukemia survivor with anthracycline-induced cardiomyopathy who was able to train and compete in a triathlon. This is an important contribution that demonstrates to an extreme the physical capabilities of cancer survivors.
The role of exercise in the prevention and treatment of anthracycline cardiotoxicity remains controversial. In animal models, beneficial effects of exercise include preservation of left ventricular systolic and diastolic function by modulating heart rate and contractility through (a) an increase in antioxidant activity with reduction of reactive oxygen species release and increase in heat shock proteins; (b) a decrease in proapoptotic signaling; (c) a decrease in myocyte turnover through suppression of proapoptotic protein synthesis; and (d) changes in energy metabolism . In humans, the data aremore limited. However, a case series of five long-term survivors of childhood cancer with subclinical anthracycline-induced cardiomyopathy demonstrated feasibility of a 12-week home aerobic and strength training program, and similar to the case report by Korn et al, survivors showed an improvement in exercise capacity and cardiopulmonary fitness (VO2 and O2 pulse). Importantly, these survivors were 25–30 years from cancer diagnosis and treatment completion, had an LVEF 40–50% at baseline, and did not experience any cardiac events or complications over the 12-week exercise program .
In the patient not exposed to potentially cardiotoxic chemotherapy, long-term excessive endurance exercise may induce pathologic structural remodeling of the heart – training and participation in “extreme” activities (marathons, triathlons) can increase pre-load and induce atrial and ventricular volume overload with liberation of cardiac troponins, and with continued training, may induce structural changes -- patchy areas of myocardial fibrosis, LV dilatation/hypertrophy and increase in myocardial mass .
This leads to a word of caution related to the intensity of exercise described in this case report. Vigorous activity with potential acute increases in catecholamines and increased energy demands can increase the risk of sudden death and acute myocardial infarction, especially in patients with underlying structural heart disease . Patients with prior anthracycline exposure may have latent mitochondrial and myocardial dysfunction that reduces cardiac reserve and could magnify that risk, and additionally, the stress of exercise without adequate reserve may lead to clinical decomposition and overt heart failure.
Risk of sudden cardiac death has also been described in cancer survivors with cancer therapy-related cardiac dysfunction. In the general population, sudden cardiac death in young athletes <35 years of age is typically due to inherited conditions (structural pathology, arrhythmias) and in older athletes >35 years of age is typically due to coronary artery disease (CAD) . Childhood cancer survivors are at risk for both – structural cardiomyopathy from direct toxic effects of chemotherapy or radiation therapy, as well as accelerated CAD, particularly if they received concurrent radiation therapy to the left chest in addition to cardiotoxic chemotherapy. The role for screening exercise testing in long-term childhood cancer survivors is not well delineated, but may be an important consideration before embarking on an intense exercise training program. In a study of screening echocardiography for more than 1800 adult survivors of childhood cancer treated with anthracycline chemotherapy (+/- radiation to the left chest), asymptomatic CAD was found in 69 patients (3.8%) and newly identified (not previously diagnosed) in 40 patients (2.2%), and valvular regurgitation or stenosis was found in 488 patients (28%), newly identified in 414 patients (23.8%) . In pilot studies, screening CT coronary angiography has identified clinically significant CAD requiring percutaneous or surgical revascularization in asymptomatic survivors of Hodgkin lymphoma exposed to mediastinal radiation therapy; larger studies are needed to determine the utility of this approach for identifying CAD in cancer survivors at high risk [7–10].
The lack of consensus in the guidelines for exercise intensity among cancer survivors at high risk of cardiovascular late effects reflects the paucity of clinical studies in this area. The International Late Effects of Childhood Cancer Guideline Harmonization Group recommends cardiology consultation for cancer survivors with known therapy-related cardiomyopathy and for cancer survivors at high risk of cardiomyopathy prior to initiation of high-intensity exercise . The American College of Sports Medicine recommends medical evaluation for adult cancer survivors with known cardiac conditions, whether treatment-related or not, to determine safe exercise limits before beginning an exercise program, but does not specifically advocate for assessment of asymptomatic survivors not known to have cardiac disease . A study of adult cancer survivors who underwent cardiopulmonary exercise testing suggested that traditional American College of Sports Medicine cardiac risk stratification – which does not account for anthracycline or radiation therapy exposure – did not adequately describe exercise risk in this population of cancer survivors .
Thorough screening history and physical exam that includes a current assessment of cardiac structure and function (echocardiogram and possibly cardiopulmonary exercise testing);
Education about possible warning “red-flag” symptoms;
Prescription for graded training with avoidance of high-risk activities, especially in the absence of adequate pre-training;
General recommendations about healthy lifestyle;
Regular supervision and follow-up with medical personnel
SS and JC contributed equally to the manuscript preparation and both authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Scott JM, Khakoo A, Mackey JR, et al. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124:642–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Smith WA, Ness KK, Joshi V, et al. Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines. Pediatr Blood Cancer. 2013;27:1132.27.Google Scholar
- O’Keefe JH, Patil HR, Lavie CJ, et al. Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. 2012;87:587–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007;115:2358–68.View ArticlePubMedGoogle Scholar
- Wasfy MM, Hutter AM, Weiner RB. Sudden Cardiac Death in Athletes. Methodist Debakey Cardiovasc J. 2016;12:76–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Mulrooney DA, Armstrong GT, Huang S, et al. Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study. Ann Intern Med. 2016;164:93–101.View ArticlePubMedPubMed CentralGoogle Scholar
- Daniels LA, Krol AD, de Graaf MA, et al. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptancedagger. Ann Oncol. 2014;25:1198–203.View ArticlePubMedGoogle Scholar
- Kupeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28:1025–30.View ArticlePubMedGoogle Scholar
- Mulrooney DA, Nunnery SE, Armstrong GT, et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer. 2014;120:3536–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol. 2008;191:32–7.View ArticlePubMedGoogle Scholar
- Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42:1409–26.View ArticlePubMedGoogle Scholar
- Kenjale AA, Hornsby WE, Crowgey T, et al. Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients. Oncologist. 2014;19:999–1005.View ArticlePubMedPubMed CentralGoogle Scholar